DYES AND PRECURSORS AND CONJUGATES THEREOF

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims priority from U.S. Provisional Applications Serial No. 60/835,407, filed on August 3, 2006, and U.S. Provisional Application Serial No. 60/835,344, filed on August 3, 2006, the contents of which are incorporated herein by reference in their entireties.

TECHNICAL FIELD

This invention relates to dyes, and to precursors and conjugates thereof.

BACKGROUND

Generally, cyanine dyes have a delocalized electron system that spans over many carbon atoms. FlG. 1 shows one such dye, 2-(2-[2-chloro-3-([l,3-dihydro- l^^-trimethyWH-indol^-ylideneJethylideneJ-l-cyclohexen-l-y^e thenyl)-!^^- trimethylindolium iodide, which is commonly known as IR-786 (I)A. The synthesis of some cyanine dyes is described in Little et al., U.S. Patent No. 6,027,709; Lugade et al., U.S. Patent No. 6,995,274, and U.S. Patent Application Publication No. 2006/0063247; Achilefu et al., U.S. Patent No. 6,939,532; and Li et al., Synthesis and Characterization of ηeptamethine Cyanine Dyes, Molecules, 2, 91-98 (1997).

Cyanine dyes, which often have an intense absorption and emission in the near-infrared (NIR) region, can be useful for biomedical fluorescence imaging because biological tissues are typically optically transparent in this region. Several studies on the use of NIR dyes, and dye-biomolecule conjugates have been published. For example, see Patonay et al., Near-Infrared Fluorogenic Labels: New Approach to an Old Problem, Analytical Chemistry, 63:321 A-327A (1991); Brinkley, A Brief Survey of Methods for Preparing Protein Conjugates with Dyes, Haptens, and. Cross- Linking Reagents, Perspectives in Bioconjugate Chemistry, pp. 59-70, C. Meares (Ed), ACS Publication, Washington, D.C. (1993); Slavik, Fluorescent Probes in Cellular and Molecular Biology, CRC Press, Inc. (1994); Lee et al., U.S. Patent No. 5,453,505; Hohenschuh et al., WO 98/48846; Turner et al., WO 98/22146; Kai et al., WO 96/17628; Snow et al., WO 98/48838; and Frangioni et al., IRDye78 Conjugates for Near-Infrared Fluorescence Imaging, Molecular Imaging, l(4):354-364 (2002).

SUMMARY

Generally, the new dyes and conjugates described herein have non-ionic solubilizing arms, which can effectively "shroud" the positive charge on the dye nucleus, reducing the overall effective charge of the molecule. This shrouding dramatically enhances the stability of the dyes and conjugates and their solubility in biological fluids. The enhanced solubility and stability of the new dyes and conjugates reduces non-specific background noise during surgery. In addition, the increased solubility enables the use of these new dyes in many biological applications.

As used herein, non-ionic solubilizing arms are neutral moieties, such as oligomers or polymers, that are capable of interacting strongly with, e.g., capable of forming hydrogen bonds with, water. Examples include polyethylene glycols (PEGs), polypropylene glycols, or copolymers of polyethylene oxide, and polypropylene oxide. For these specific examples, each oxygen atom on the molecular arm can interact strongly with a molecule of water.

More particularly, some of the new dyes herein include a positively charged nitrogen-containing dye core that includes a conjugated tri-, penta-, or heptamethine system. As used herein, "a heptamethine system" is an uninterrupted molecular fragment that includes seven methine groups (CH groups) and having a dclocalized electron density, whereas tri-, and penta-methine moieties include three and five methine groups, respectively. The dye core has one or more non-ionic solubilizing molecular arms and, optionally, one or more functionalizable molecular arms bonded thereto. When present, the one or more functionalizable molecular arms include an amine-, alcohol-, or thiol-reactive carboxylic acid group, anhydride group, ester group, or isothiocyanate group. As used herein, "a functionalizable molecular arm" is a moiety that can be conjugated. For example, the molecular arm can be conjugated with a protein, or a carbohydrate. The dye core can include a single positive charge, or multiple charges. The tri-, penta- or heptamethine system can be substituted or unsubstituted.

Generally, the dyes have a high solubility in vitro, and in biological systems. For example, the one or more solubilizing molecular arms can be selected such that the dyes have a solubility in 10 mM HEPES solution (N-(2-hydroxyethyl)piperazine- N'-(2-ethanesulfonic acid)), pH 7.4, of greater than about 10 μM, e.g., greater than 25, 50, 75, 100, 125, 150, or even greater than 250 μM. If desired, the one or more

sohibilizing arms can also be functionalized with an amine-, alcohol-, or thiol-reactive carboxylic acid group, anhydride group, ester group, or isothiocyanate group. Generally, the dyes have an intense absorption and/or emission at a wavelength of from about 300 run to 1000 nm, and thus emit in the green, yellow, orange, red, and near infrared portions of the spectrum. For example, the dyes can have a maximum excitation and/or a maximum emission, measured in 10 mM HEPES solution, pH 7.4, of from about 525 nm to about 875 nm, e.g., from about 550 nm to about 825 nm, or from about 550 nm to about 800 nm.

The one or more non-ionic solubilizing molecular arms can be, e.g., a polyethylene glycol, e.g., one terminated with a hydroxyl group or a alkoxy group. Conjugates can be formed by reacting the dyes with one or more molecular arms having suitable functionality, e.g., an amine-, alcohol-, or thiol-reactive carboxylic acid group, anhydride group, ester group, or isothiocyanate group. For example, such functionalized molecular arms can be conjugated with an amino-, hydroxyl-, or thiol- containing moiety, such as a small molecule peptide, protein, a polypeptide, or a carbohydrate.

In one aspect, the invention features compounds that include cations of Structure (I), which is shown below.

(I)

In such an aspect, Sj, and S ₂ are each independently a non-ionic oligomeric or polymeric solubilizing moiety; n.| is 1, 2 or 3; Ri, R ₂ , R3, RO, R7, and Rg are each independently H, F, Cl, Br, I, C1-C6 straight-chain or branched alkyl, C1-C6 straight- chain or branched alkoxy, an aromatic ring having up to 6 carbon atoms, optionally substituted with one or more F, CI, Br or I. Any two or more of Ri , R ₂ and R3 and/or any two or more of Re, R ₇ and Rj may be bonded together to define a ring that includes between 5 and 12 carbon atoms. The ring that includes between 5 and 12 carbon atoms can be optionally substituted with one or more F, Cl, Br, or I. R4 and Rs

are each independently C1-C6 straight-chain or branched alkyl, an aromatic ring having up to 6 carbon atoms, optionally substituted with one or more F, Cl, Br or I, a non-ionic oligomeric or polymeric solubilizing moiety, or a moiety that includes at least one amine-, alcohol- or thiol-reactive carboxylic acid group, anhydride group, ester group, or isothiocyanate group. In some embodiments, the moiety that includes at least one amine-, alcohol-, or thiol-reactive carboxylic acid group, anhydride group, ester group, or isothiocyanate group also includes a solubilizing moiety.

In some embodiments, the compounds have cations which have a trimethine system represented by Structure (I'), a pentamethine system represented of Structure (1") or a heptamethine system represented by Structure (I'")-

(I")

U ₁ =3 (I'")

In another aspect, the invention features compounds of Structure (V), which is shown below.

(V)

In such an aspect, Si is a non-ionic oligomeric or polymeric solubilizing moiety; and Ri, R ₂ , R ₃ are each independently H, F, Cl, Br, I, C1-C6 straight-chain or branched alkyl, C1-C6 straight-chain or branched alkoxy, an aromatic ring having up to 6 carbon atoms, optionally substituted with one or more F, Cl, Br or I. Any two or more of Ri, R ₂ and R ₃ may be bonded together to define a ring that includes between 5 and 12 carbon atoms. The ring that includes 5-12 carbon atoms is optionally substituted with one or more F, Cl, Br, or I.

In another aspect, the invention features compounds that include cations of Structure (Vl), which is shown below.

In such an aspect, Si is a non-ionic oligomeric or polymeric solubilizing moiety; and Ri, R. ₂ , R3 are each independently H, F, Cl, Br, I, C1-C6 straight-chain or branched alkyl, C1-C6 straight-chain or branched alkoxy, an aromatic ring having up to 6 carbon atoms, optionally substituted with one or more F, Cl, Br, or 1. Any two or more of Ri, R ₂ and R ₃ may be bonded together to define a ring that includes between 5 and 12 carbon atoms. The ring that includes 5-12 carbon atoms is optionally substituted with one or more F, Cl, Br, or I. R ₄ is independently Cl -C6 straight-chain or branched alkyl, an aromatic ring having up to 6 carbon atoms, optionally substituted with one or more F, Cl, Br or I, a non-ionic oligomeric or polymeric solubilizing moiety, or a moiety that includes at least one amine, alcohol- or thiol- reactive carboxylic acid group, anhydride group, ester group, or isothiocyanate group.

In another aspect, the invention features compounds that include cations of Structure (VIII), which is shown below.

(VIII)

In such an aspect, S ₃ , S ₄ , S$, and Se are each independently a non-ionic oligomeric or polymeric solubilizing moiety; n ₂ is 1, 2 or 3; Rio, Rn, R12, R ₁ 3, R16, Rn, Ris, and Ri? are each independently H, F, Cl, Br, I, C1-C6 straight-chain or branched alkyl, C1-C6 straight-chain or branched alkoxy, an aromatic ring having up to 6 carbon atoms, optionally substituted with one or more F, Cl, Br or I. Any two or more of Rio, Ri ₁ , R ₁₂ , and Rn and/or Ri ₆ , Rn, Ru, and R ₁ 9 may be bonded together to define a ring that includes between 5 and 12 carbon atoms. The ring that includes 5-12 carbon atoms is optionally substituted with one or more F, Cl, Br, or I. RH and R ₁₅ are each independently C1-C6 straight-chain or branched alkyl, an aromatic ring having up to 6 carbon atoms, optionally substituted with one or more F, Cl, Br or I, a non-ionic oligomeric or polymeric solubilizing moiety, or a moiety that includes at least one amine-, alcohol- or thiol-reactive carboxylic acid group, anhydride group, ester group, or isothiocyanate group.

In some embodiments, the compounds have cations which have a trimethinc system represented by Structure (VIlI'), a pentamethine system represented of Structure (VIII") or a heptamethine system represented by Structure (VIH'").

(VIII")

n ₂ = 3

(vm'")

In another aspect, the invention features compounds of Structure (XII), which n below.

(XII)

In such an aspect, S ₃ and S ₄ are each independently a non-ionic oligomeric or polymeric solubilizing moiety; and Rio, Ru, R ₁₂ , and Rn are each independently H, F, Cl, Br, I, C1-C6 straight-chain or branched alkyl, C1-C6 straight-chain or branched alkoxy, an aromatic ring having up to 6 carbon atoms, optionally substituted with one or more F, Cl, Br, or 1. Any two or more of Rio, Ri i, Rn, and R13 may be bonded together to define a ring that includes between 5 and 12 carbon atoms. The ring that includes 5-12 carbon atoms is optionally substituted with one or more F, Cl, Br, or I.

In another aspect, the invention features compounds that include cations of Structure (XIII), which is shown below.

(XIII)

In such an aspect, S ₃ and S ₄ are each independently a non-ionic oligomeric or polymeric solubilizing moiety; Rio, Rn, R ₁₂ , and Ru are each independently H, F, Cl, Br, I, C1-C6 straight-chain or branched alkyl, Cl -C6 straight-chain or branched alkoxy, or an aromatic ring having up to 6 carbon atoms, optionally substituted with

one or more F, Cl, Br, or I. Any two or more of Rio, Rn, Rn, and R13 may be bonded together to define a ring that includes between 5 and 12 carbon atoms. The ring that includes 5-12 carbon atoms is optionally substituted with one or more F, Cl, Br, or I. Ru is C1-C6 straight-chain or branched alkyl, an aromatic ring having up to 6 carbon atoms, optionally substituted with one or more F, Cl ₁ Br or 1, a non-ionic oligomeric or polymeric solubilizing moiety, or a moiety that includes at least one amine-, alcohol- or thiol-reactive carboxylic acid group, anhydride group, ester group, or isothiocyanate group.

Aspects and/or embodiments of the invention can have any one of, or combinations of, any of the following advantages. The dye precursors, dyes, and conjugates have a high solubility in aqueous solutions, and biological fluids and tissues. The dyes and conjugates have non-ionic solubilizing arms, which can effectively "shroud" the positive charge on the nitrogen atoms, reducing the overall effective charge of the molecule. Reducing the overall effective charge minimizes non-specific background noise during imaging. The dyes and conjugates can be used for real time surgical guidance for identifying tumors and other abnormal tissues. The dyes and conjugates have a high in vivo stability. The dyes can be easily conjugated with targeting molecules, such as those that contain an amino, thiol, and/or hydroxyl functionality. The dyes and conjugates retain high fluorescent yield at about 800 nm, which is often optimal for in vivo imaging. Solubilizing arms on the dyes and conjugates have a length that can be adjusted to optimize biodistribution and clearance. The solubilizing arms of the dyes and conjugates can reduce non-specific background binding in vivo. The dyes and conjugates can have a low overall toxicity.

For the purposes of this disclosure, 10 mM HEPES solution, pH 7.4, is a pH adjusted, 10 mM solution of N-(2-hydroxyethyl)piperazine-N'-(2-ethanesulfonic acid).

For mixtures of materials, such as mixtures of monomelic compounds or polymeric compounds that have a molecular weight distribution, solubility is the average solubility of the dye core.

An "oligomer" as used herein, is a relatively low molecular weight polymer having between about 4 and about 25 repeat units.

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to

which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference herein in their entirety. In case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.

Other features and advantages of the invention will be apparent from the following detailed description, and from the claims.

DESCRIPTION OF DRAWINGS

FIG 1 is a resonance structure for 2-(2-[2-chloro-3-([l,3-dihydro-l,3,3- trimethyl-2H-indol-2-ylidene]ethylidene)-l-cyclohexen-l-yl]e thenyl)-l,3,3- trimethylindoKum iodide (IR-786, (I)A).

FIG. 2A is a generalized reaction scheme, illustrating attachment of solubilizing arms onto functionalized anilines.

FIG. 2B is a representation of eight structures of specific functionalized anilines and corresponding anilines having attached solubilizing arms.

FIG. 3 is a generalized reaction scheme, illustrating preparation of diazonium salts (not shown) corresponding to the anilines of FIG. 2 having the solublizing arms, and then reduction of the diazonium salts to produce the corresponding hydrazines.

FIG. 4 is a generalized reaction scheme, illustrating cyclization of the hydrazines of FIG. 3, utilizing methyl isopropyl ketone and the Fischer indole reaction.

FIG. 5 is a generalized reaction scheme, illustrating quaternization of the cyclized products of FIG. 4.

FIG. 6 is a representation of four specific structures that can be used to quatemize the cyclized products of FIG. 5.

FIG. 7 is a generalized reaction scheme, illustrating coupling of the quaternized products of FIG. 5.

FIG. 8 is a generalized reaction scheme, illustrating preparation of other diazonium salts (not shown) from the shown anilines having solubilizing arms, and then reduction of the diazonium salts to produce the corresponding hydrazines.

FIG. 9 is a generalized reaction scheme, illustrating cyclization of the hydrazines of FIG. 8, utilizing methyl isopropyl ketone and the Fischer indole reaction.

FIG. 10 is a generalized reaction scheme, illustrating coupling of quaternized products corresponding to the cyclized products of FIG. 9.

FIG. 1 1 is a generalized reaction scheme showing the preparation of a conjugate from a dye and a hydroxyl-containing moiety, e.g., a carbohydrate.

FIG. 12 is a generalized reaction scheme, illustrating the preparation of a conjugate from a dye and an amino-containing moiety, e.g., a protein.

DETAILED DESCRIPTION

Novel dyes are provided that include non-ionic solubilizing moieties, such as polyethylene glycols (PEGs). In many embodiments, the dyes can be conjugated, e.g., by reacting the dyes with a small molecule peptide, a protein or a carbohydrate, to provide imaging agents that can bind selectively to certain tissues, e.g., abnormal tissues, allowing for their imaging. For example, dyes and conjugates can be used for real time surgical guidance for identifying tumors, and other abnormal tissues.

Dyes

Some dyes are provided that include cations represented by Structure (I), which is shown below.

(D In dyes that include cations of Structure (I), Sj, and S ₂ are each independently a non-ionic oligomeric or polymeric solubilizing moiety.

For example, each non-ionic oligomeric or polymeric solubilizing moiety can be a polyethylene glycol, a polypropylene glycol, a copolymer of polyethylene oxide and propylene oxide, a carbohydrate, a detran, or a polyacrylamide. Each solubilizing moiety on a particular molecule can be the same or different.

Each solubilizing moiety can be attached to the dye nucleus by any desired mode. For example, a moiety can be attached to the dye nucleus by bonding a terminal end (e.g., that contains a hydroxyl group), or a non-terminal end of the moiety to the dye nucleus. The point of attachment of the dye nucleus to the solubilizing moiety can be, e.g., a carbon-carbon bond, a carbon-oxygen, or a nitrogen-carbon bond. The attachment group for the solubilizing moiety to the dye nucleus can be, e.g., an ester group, a carbonate group, a ether group, a sulfide group, an amino group, an alkylene group, an amide group, a carbonyl group, or a phosphate group.

Specific examples of solubilizing groups arc polyethylene glycols, such as -OCX=O)O(CH ₂ CH ₂ O) _n H, -OCt=O)O(CH ₂ CH ₂ O) _n CH ₃ , -0(CH ₂ CH ₂ O) _n CH ₃ , -S(CH ₂ CH ₂ O) _n CH ₃ , n being an integer between about 10 and about 250; and dextrans, such as -OC(=O)O(dextran).

Each solubilizing moiety can have an absolute molecular weight of from about 500 amu to about 100,000 amu, e.g., from about 1,000 amu to about 50,000 amu, or from about 1,500 to about 25,000 amu.

In some embodiments, Si, and S ₂ are selected such that the dyes that include the cations of Structure (I) have a solubility in 10 mM HEPES solution, pH 7.4, of greater than about 10 μM, e.g., greater than 25, 50, 75, 100, 125, 150, 200, or even greater than 250 μM. Solubility can be determined photometrically at 25 ⁰ C by setting up a calibration curve using a base dye core; saturating a 10 mM HEPES solution, pH 7.4, with the test compound or mixture, and then determining where on the calibration curve the test compound or mixture falls.

In some specific embodiments, Si and S ₂ of compounds of Structure (I), are each independently of the form R ₉ (α)φ, wherein φ is 0 or 1, α is O, S, CH ₂ , CH ₂ O, CO ₂ , or NR' in which R' is H or C1-C6 straight-chain or branched alkyl. In such instances, R ₉ is of the form (CH ₂ CH ₂ O) ₁₁₃ R" in which R" is H or C1-C6 straight-chain or branched alkyl, n ₃ being an integer from 4 to 2,500. In such pegylated dyes, when φ takes on the value of 0, α is not present, and R ₉ is bonded directly to the indicated

benzene ring. In particular embodiments, n ₃ is between 6 and 2,000, e.g., between 10 and 1,000 or between 10 and 750.

In some specific embodiments, the PEG chain length and the PEG end group are selected such that the dyes that include the cations of Structure (I) have a solubility in 10 mM HEPES solution, pH 7.4, of greater than about 10 μM, e.g., greater than 25, 50, 75, 100, 125, 150, 200, or even greater than 250 μM.

In some specific embodiments, α is O or S and Si, and S ₂ are each independently of the form (CH ₂ CH ₂ O) _nS R", in which R" is H and n ₃ is an integer from 10 to 1,000.

In the dyes that include cations of Structure (I), ni is 1, 2 or 3, corresponding respectively to a compound having a trimethine spacer bridging nitrogen-containing heterocyclic rings, compounds having a pentamethine spacer and compounds having a heptamethine spacer bridging nitrogen-containing heterocyclic rings. In particular, compounds having a trimethine spacer, a pentamethine spacer and a heptamethine spacer are represented by Structures (I ¹ ), (I") and (V"), respectively (shown below).

(I")

n, -3

(I'")

In dyes that include cations of Structure (I), R], R ₂ , R ₃ , R _O , R ₇ , and Rg are each independently H, F, Cl, Br, I, C1-C6 straight-chain or branched alkyl, C1-C6 straight- chain or branched alkoxy, an aromatic ring having up to 6 carbon atoms, optionally substituted with one or more F, Cl, Br or I, or any two or more OfR ₁ , R ₂ and R ₃ and/or R ₆ , R ₇ and Rg may be bonded together to define a ring that includes between 5 and 12 carbon atoms. The 5-12 carbon ring can be optionally substituted with one or more F, Cl, Br, or I. The ring that includes between 5 and 12 carbon atoms can a carbocyclic ring (e.g., a carbocyclic aromatic ring such as a phenyl group or a substituted phenyl group), or a heterocyclic ring (e.g., a heterocyclic aromatic ring, such as one containing nitrogen, oxygen sulfur or phosphorus).

In some specific embodiments, R|, R ₂ , R ₃ , Re, R ₇ , and Rg are each H.

In dyes that include cations of Structure (I), R ₄ and R ₅ are each independently C1-C6 straight-chain or branched alkyl, an aromatic ring having up to 6 carbon atoms, optionally substituted with one or more F, Cl, Br, or I, a non-ionic oligomeric or polymeric solubilizing moiety, or a moiety that includes at least one amine-, alcohol- or thiol-reactive carboxylic acid group, anhydride group, ester group, or isothiocyanate group.

The moiety that includes at least one amine-, alcohol- or thiol-reactive carboxylic acid group, anhydride group, ester group, or isothiocyanate group allows the dyes to be conjugated with another compound that includes an amino group (e.g., a small molecule peptide, or a protein), an alcohol group (e.g., a carbohydrate), or a thiol group; or a non-ionic oligomeric or polymeric solubilizing moiety. If desired, e.g., to improve solubility or biocompatibility, the moiety that includes at least one

e.g., to improve solubility or biocompatibility, the moiety that includes at least one amine-, alcohol- or thiol-reactive carboxylic acid group, anhydride group, ester group, or isothiocyanate group can include any of the solubilizing moieties discussed herein. For example, the solubilizing group can act as a spacer between the dye nucleus and the amine-, alcohol- or thiol-reactivc carboxylic acid group, anhydride group, ester group, or isothiocyanate group.

In some specific embodiments, R ₄ is

and R ₅ is CI-C6 straight or branched alkyl, e.g., methyl, ethyl, isopropyl, or n-pentyl.

In some specific embodiments, both R ₄ and R ₅ include a moiety that includes at least one amine-, alcohol- or thiol-reactive carboxylic acid group, anhydride group, ester group, or isothiocyanate group, allowing both R ₄ and R ₅ to be conjugated.

Examples of C1-C6 straight-chain or branched alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-pentyl, isopentyl and neopentyl. Examples of C1-C6 straight-chain or branched alkoxy groups include methoxy, ethoxy, n-propoxy, isopropoxy, n-pentoxy, isopentoxy and neopentoxy.

Examples of aromatic ring systems having up to 6 carbon atoms, optionally substituted with one or more F, Cl, Br, or I, include phenyl groups or substituted phenyl groups (e.g., an attached benzene ring having 1 ,2-dichloro substitution or 1 - chloro-4-fluoro substitution), and heterocyclic aromatic groups or substituted heterocyclic aromatic groups, such as furan, thiophene, imidazole, pyrazole, oxazole, pyridine, and their substituted derivatives.

Any of the compounds of Structure (I) can have a counterion (A ^" ) that is inorganic, such as F ^" , Cl ^" , Br ^" , I ^" , CIO ₄ ^" , or a counterion that is organic, such as CH ₃ COO ^" , formate ion, or citrate ion.

Some dyes are provided that include cations represented by Structure (VHI), which is shown below.

(VIII)

In dyes that include cations of Structure (VIII), S ₃ , S ₄ , S ₅ and S _δ are each independently a non-ionic oligomeric or polymeric solubilizing moiety.

In some embodiments, S ₃ , S ₄ , Ss and Se are selected such that the dyes that include the cations of Structure (VIH) have a solubility in 10 mM HEPES (N-(2- hydroxyethyl)piperazine-N'-(2-ethanesulfonic acid)) solution, pH 7.4, of greater than about 10 μM, e.g., greater than 25, 50, 75, 100, 125, 150, 200, or even greater than 250 μM.

Each solubilizing moiety can be any of those discussed above in reference to Structure (I). For example, each non-ionic oligomeric or polymeric solubilizing moiety can be a polyethylene glycol, which is attached to the dye nucleus by any of the modes discussed above. Each solubilizing moiety can have an absolute molecular weight as discussed above. For example, the absolute molecular weight of each solubilizing moiety can be from about 1,000 amu to about 50,000 amu.

In some specific embodiments, S ₃ , S ₄ , S ₅ and Se of compounds of Structure (VIlI) are each independently of the form R. ₉ (α) _φ , wherein φ is 0 or 1, α is O, S, CH ₂ , CH ₂ O, CO ₂ , or NR' in which R' is H or C1-C6 straight-chain or branched alkyl. In such instances, R ₉ is of the form (CH ₂ CH ₂ O) _n3 R" in which R" is H or C1-C6 straight- chain or branched alkyl, n ₃ being an integer from 4 to 2,500.

In the dyes that include cations of Structure (VIII), n ₂ is 1, 2, or 3, corresponding respectively to a compounds having a trimethine spacer bridging nitrogen-containing heterocyclic rings, compounds having a pcntamethine spacer, and compounds having a heptamethine spacer bridging nitrogen-containing heterocyclic rings. In particular, compounds having a trimethine spacer, a pentamethine spacer,

and a heptamethine spacer are represented by Structures (VIII'), (VIII") and (VIH'"), respectively (shown below).

(vπr)

(VIII")

(VIII'")

In dyes that include cations of Structure (VHI), Rio, Rn, R ₁₂ , R13, Ri6 _> Rπ _> Rm, and Ri ₉ are each independently H, F, Cl, Br, I, C1-C6 straight-chain or branched alkyl, C1-C6 straight-chain or branched alkoxy, an aromatic ring having up to 6 carbon atoms, optionally substituted with one or more F, Cl, Br or I, or any two or more of Rio, Rn, R ₁₂ , and R ₁₃ and/or Riβ, Rn, Rig, and R^may be bonded together to define a ring that includes between 5 and 12 carbon atoms. The 5 to 12 carbon atom ring can be optionally substituted with one or more F, Cl, Br, or I.

In dyes that include cations of Structure (VIII), Ri ₄ and Ri ₅ are each independently Cl -C6 straight-chain or branched alkyl, an aromatic ring having up to 6 carbon atoms, optionally substituted with one or more F, Cl, Br or I, a non-ionic oligomeric or polymeric solubilizing moiety, or a moiety that includes at least one amine-, alcohol- or thiol-reactive carboxylic acid group, anhydride group, ester group, or isothiocyanate group.

In some specific embodiments, both Ri ₄ and R ₁₅ include a moiety that includes at least one amine-, alcohol- or thiol-reactive carboxylic acid group, anhydride group, ester group, or isothiocyanate group, allowing both R ₎₄ and R ₁₅ to be conjugated.

Examples of C1-C6 straight chain or branched alkyl, C1-C6 straight-chain or branched alkoxy, aromatic rings having up to 6 carbon atoms, and the moiety that includes at least one amine-, alcohol-, or thiol-reactive carboxylic acid group, anhydride group, ester group, or isothiocyanate group have been discussed above. If desired, e.g., to improve solubility or biocompatibility, the moiety that includes at least one amine-, alcohol- or thiol-reactive carboxylic acid group, anhydride group, ester group, or isothiocyanate group can include any of the solubilizing moieties discussed above. For example, the solubilizing group can act as a spacer between the dye nucleus and the amine-, alcohol- or thiol-reactive carboxylic acid group, anhydride group, ester group, or isothiocyanate group. When any two or more of Rio, Rn, R ₁₂ , and Ru and/or R ₁ 6, Rn, R ₁₈ , and R ₁ 9 are bonded together to define a ring that includes between 5 and 12 carbon atoms (which is optionally, substituted with one or more F, Cl, Br, or I), the ring can be carbocyclic or heterocyclic, as discussed above in reference to compounds of Structure (I).

Any of the compounds of Structure (VIII) can have a counterion (A ^" ) that is inorganic, such as F ^' , Cl ^" , Br ^" , I ^" , ClO ₄ ^" , or a counterion that is organic, such as CH ₃ COO ^" , formate ion, or citrate ion.

Absorption and Emission Properties of the Dyes

Generally, the dyes intensely absorb and emit light in the visible, and infrared region of the electromagnetic spectrum, e.g., they can emit green, yellow, orange, red light, or near-infrared ("NIR") light.

In some embodiments, the dyes emit and/or absorb radiation having a wavelength from about 300 nm to about 1000 nm, e.g., from about 400 nm to about 900 nm, or from about 450 nm to about 850 nm.

In some embodiments, the dyes have a maximum excitation and/or a maximum emission, measured in 10 mM HEPES solution, pH 7.4, of from about 525 nm to about 875 nm, e.g., from about 550 nm to about 825 nm, or from about 550 nm to about 800 nm.

Methods of Preparing the Dyes

As an overview, FIGS. 2A-7 show that dyes of Structure (I)A (FIG. 7), which include cations of Structure (I), can be prepared by first attaching solubilizing arms onto the desired functionalized anilines (FIG. 2A). The resulting anilines having the solubtlizing arms are converted to the corresponding hydrazines (FIG. 3), and then the hydrazines are cyclized using methyl isopropyl ketone and the Fischer Indole reaction (FIG. 4). The heterocycles thus formed are then quaternized by attachment of groups or arms, e.g., solubilizing arms, to the nitrogen atom of each heterocycle (FIG. 5). Finally, the quaternized heterocycles are coupled using the desired formamidine or dienylidene (VH) (FIG. 7). This particular synthetic scheme is described in a little more detail below.

Referring particularly to FIG. 2A, functionalized anilines of Structures (II) and (H') arc reacted with S'i or S' ₂ , respectively, converting each respective functional group f] or f ₂ to solubilizing arms Si or S ₂ , to generate anilines of Structures (III) and (III'). Functional groups fi and f ₂ can be, e.g., a carboxylic acid group (or an ester thereof), or a phenolic oxide group (formed by deprotonating a phenolic hydroxyl group), and S'i or S' ₂ can be, e.g., α,ω-di-hydroxy polyethylene oxide, dextran, or ethylene oxide. Rj, R ₂ , and R ₃ can be any of the groups described above in reference to Structure (I) above. Specific examples of the functionalized anilines prior to attaching solubilizing arms include those shown in FIG. 2A (i.e.,

compounds 2, 2', 2" and 2'" ). Specific examples of anilines having attached solubilizing arms are also shown in FIG. 2B (i.e., compound 3, 3', 3" and 3'").

Referring particularly to FIG. 3, anilines having solubilizing arms represented by Structures (III) and (HI') are each reacted with, e.g., NaNO ₂ , which produces each respective diazonium salt (not shown). Reduction of each diazonium salt, e.g., using Na ₂ SCh, generates the corresponding hydrazine, represented by Structure (IV) or (IV).

Referring particularly to FIG. 4, hydrazines of Structures (IV) and (IV) are each cyclized using methyl isopropyl ketone and the Fischer Indole reaction, generating the corresponding heterocycles, represented by Structures (V) and (V).

Referring particularly to FIG. 5, neutral heterocycles of Structures (V) and (V) are quaternized using, e.g., R ₄ A and R ₅ A, respectively, generating quaternized heterocyclic compounds of Structures (VI)A and (VT)A, A being the counterion (e.g., CY, Bf, or Y). If desired, R ₄ A and RsA can be, e.g., a solubilizing moiety that includes a good leaving group, such as a halogen. In particular embodiments, R ₄ A and/or R ₅ A are polyethylene glycols that have a terminal bromide and terminal amine- , alcohol- or thiol-reactive carboxylic acid group, anhydride group, ester group, or isothiocyanate group. Specific examples OfR ₄ A and R ₅ A are shown in FIG. 6 (i.e., compounds 5, 6, 7, 8, and 9)

Referring particularly to FIG. 7, quaternized heterocyclic compounds of Structures (VI)A and (VI')A are coupled by first reacting one Of(VI)A or (VI')A with (VII), and then reacting the reaction product with (VI)A or (VT')A.

As an overview, FIGS. 8- 10 show that dyes of Structure (VIII)A (FIG. 10), which include cations of Structure (VIII), can be prepared by first attaching solubilizing arms onto the desired functionalized anilines (not shown, but analogous to that shown in FIG. 2). The resulting anilines having the solubilizing arms are converted to the corresponding hydrazines (FIG. 8), and then the hydrazines are cyclized using methyl isopropyl ketone and the Fischer Indole reaction (FIG. 9). The heterocycles thus formed are then quaternized (not shown, but analogous to that shown in FIG. 5). Finally, the quaternized heterocycles are coupled using the desired formamidine or dienylidene (VII) (FIG. 10). This particular synthetic scheme is described in a little more detail below.

Functionalized anilines are reacted with S ' ₃ and S '4, and S ' ₅ and S '(,, respectively, converting each respective functional group f ₃ and £», and f _$ and f _<5 to solubilizing arms S3 and S ₄ or S ₅ and Se, to generate anilines of Structures (IX) and (IX'). S ₃ -S _δ and R ₁₀ -R ₁ 9, can be any of the groups described above in reference to Structure (VIII) above.

Referring particularly to FIG. 8, anilines having solubilizing arms represented by Structures (IX) and (IX') are each reacted with, e.g., NaNO ₂ , which produces each respective diazonium salt (not shown). Reduction of each diazonium salt, e.g., using Na ₂ SC>3, generates the corresponding hydrazine, represented by Structure (X) or (X').

Referring particularly to FIG. 9, hydrazines of Structures (X) and (X') are each cyclized using methyl isopropyl ketone and the Fischer Indole reaction, generating the corresponding heterocycles, represented by Structures (XII) and (XII').

Neutral heterocycles of Structures (XU) and (XII') are then each quaternized using, e.g., R ₁₄ A and R ₁₅ A, respectively, generating quaternized heterocyclic compounds of Structures (XIII)A and (XIII ')A, A being the counterion (e.g., Cl ^" , Br ^" , or Y). If desired, R ₁ 4A and R ₁₅ A can be, e.g., a solubilizing moiety that includes a good leaving group, such as a halogen. In particular embodiments, R ₁₄ A and/or R ₁₅ A are polyethylene glycols that have a terminal bromide and terminal amine-, alcohol- or thiol-reactive carboxylic acid group, anhydride group, ester group, or isothiocyanate group.

Referring particularly to FIG. 10, quaternized heterocyclic compounds of Structures (XIII)A and (XIH')A are coupled by first reacting one of (XIII)A or (XIII ')A with (VII), and then reacting the reaction product with (XIII)A or (XIII ')A.

When desired and/or necessitated to effect any chemical transformation, any of the functional groups in any of the synthetic schemes shown herein can be protected by protecting groups, which can be removed in a later step to produce the desired compound.

Other synthetic schemes that can be applied to making dyes are described in Frangioni et al., U.S. Provisional Patent Application Serial No. 60/835,344, filed August 3, 2006.

Dye Conjugates

Any of the dyes described herein, e.g., dyes that include cations of Structures (I), (VIII) can be reacted with other compounds, e.g., oligomers or polymers that contain amine-, alcohol-, or thiol-groups, such as targeting ligands (e.g., small molecule peptides, proteins, protein fragments, peptides, antibodies, carbohydrates, or antigens), to provide conjugates. For example, FIGS. 11 and 12 show, respectively, reaction of dyes of Structure (XV)A with hydroxyl-containing moieties, and amine- containing moieties.

In a typical conjugation procedure, all of the following steps can be performed under reduced light conditions in dimethyl sulfoxide (DMSO) at room temperature. In one procedure, each 50 μL reaction contains 20 mM triethylamine (TEA), 1 mM of the desired ligand, and 1 mM of the desired dye. To effect the conjugation, the reaction mixture is constantly agitated for 18 hours in the dark. Additional general details for conjugation of dyes is discussed in Frangioni et al., Molecular Imaging, vol. 1(4), 354-364 (2002).

Specific proteins, protein fragments, peptides, antibodies, carbohydrates, or antigens that can be used to form the new conjugates are described, e.g., in Frangioni et al. in "MODIFIED PSMA LIGANDS AND USES RELATED THERETO", WO 02/098885, filed on February 7, 2002 (now issued as U.S. Patent No. 6,875,886). A specific targeting ligand is the RGD peptide, which specifically binds to alph _av β ₃ intcgrin. It is known that this integrin is ovcrexpressed by various tumors, and thus, these RGD targeting peptides enable the dyes to preferentially label tumors that overexpress these integrins. Other targeting ligands include melanocyte stimulating hormone (MSH), which targets melanoma cells, or bombesin, somatostatin, or Sandostatin™ (synthetic), which target somatostatin receptors.

Applications

The dyes and dye conjugates, e.g., dye-biomolecule conjugates, can be used for, e.g., optical tomographic, endoscopic, photoacoustic, and sonofluorescent applications for the detection, imaging, and treatment of tumors and other abnormalities.

The dyes and dye conjugates can also be used for localized therapy. This can be accomplished, e.g., by attaching a porphyrin or other photodynamic therapy agent

conjugates to accumulate selectively in the target site; and shining light of an appropriate wavelength to activate the agent. Thus, the new conjugates can be used to detect, image, and treat a section of tissue, e.g., a tumor. In addition, the dyes and conjugates can be used for detecting the presence of tumors and other abnormalities by monitoring the blood clearance profile of the conjugates, for laser assisted guided surgery for the detection of small micrometastases of, e.g., somatostatin subtype 2 (SST-2) positive tumors, and for diagnosis of atherosclerotic plaques and blood clots.

Dyes and Dye Conjugate Compositions

The dyes and dye conjugates can be formulated into diagnostic and therapeutic compositions for enteral, or parenteral administration. Generally, these compositions contain an effective amount of the dye or dye conjugate, along with conventional pharmaceutical carriers and excipients appropriate for the type of administration contemplated. For example, parenteral formulations include the dye or dye conjugate in a sterile aqueous solution or suspension. Parenteral compositions can be injected directly into a subject at a desired site, or mixed with a large volume parenteral composition for systemic administration. Such solutions can also contain pharmaceutically acceptable buffers and, optionally, electrolytes, such as sodium chloride.

Formulations for enteral administration, in general, can contain liquids, which include an effective amount of the desired dye, or dye conjugate in aqueous solution, or suspension. Such enteral compositions can optionally include buffers, surfactants, and thixotropic agents. Compositions for oral administration can also contain flavoring agents, and other ingredients for enhancing their organoleptic qualities.

Generally, the diagnostic compositions are administered in doses effective to achieve the desired signal strength to enable detection. Such doses can vary, depending upon the particular dye or dye conjugate employed, the organs or tissues to be imaged, and the imaging equipment being used. For example, Zeheer et al., Nature Biotechnology, 19, 1148-1154 (2001) uses 0.1 μmol/kg as a dose for IRDye78 conjugates in vivo. The diagnostic compositions can be administered to a patient systemically, or locally to the organ, or tissue to be imaged, and then the patient is subjected to the imaging procedure.

OTHER EMBODIMENTS

A number of embodiments have been described. Nevertheless, it will be understood that various modifications may be made without departing from the spirit and scope of the invention. Other embodiments are within the scope of the following claims.